
Latest
Make well informed decisions, quickly through industry leading process simulation, economic analysis software.



Sustainability Interview – Life Cycle Assessment
Today we have a special guest – Bill Flanagan to give us great insight into Sustainability in our industry. It is such a pleasure to be able to interview someone who has numerous publications related to sustainability. Our Sales & Marketing Director Dr Yuki Abe

UK biomanufacturing team to spearhead development of advanced controls to accelerate drug and vaccine manufacturing

Plasmid DNA, mRNA and Viral Vectors – the Building Blocks of Cell and Gene Therapy Processing

Biopharm Services Interview McMaster University Part 1
Biopharm Services and McMaster University is kicking off the collaboration project to conduct Cell Therapy and Gene Therapy modelling together. Here is our interview with them. Good morning to you, David. Would you kindly introduce yourself to our audience? I’m an

Interview with Javier Lozano from SDD™
What is your name and your involvement to SDD™? My name is Javier Lozano, I am the Technical Lead for the SDD™ innovation, as well as the Process Engineering Head of Department for PM Group in the UK. Can you explain about SDD™ – what

Antibody Drug Conjugates aren’t “too expensive” – how can the costs of manufacture be monitored and improved?
The historical development of antibody drug conjugates is a well told yarn, where self-immolating reactions are scribbled on ESACT conference paper with PEGS free-issue pens. These multidisciplinary scientists and the molecules they make are writing a new storyline now. Increased activity With six approvals of

Biopharm Interview with University of Natural Resources and Life Sciences Vienna
General questions What are your name, organization name and position? D Alessandro Luigi Cataldo, PhD candidate at the University of Natural Resources and Life Sciences Vienna (when the interview has been conducted Summer 2020, Alessandro was still at BOKU University; he

Regeneron’s High Profile Success? Demand for COVID-19 prophylactics – what role for Pichia expression technology to assist access
With Regeneron’s high profile, single-person, single-site, clinical trial proving successful (along with much supporting other clinical data!), will neutralising antibodies surf the second wave? Our COVID-related blogs focus on capacity and cost of making the treatments and understanding opportunities or bottlenecks in large scale provision

Biopharm interview with Dr David Pollard
General questions What is your name, company name and position? D Dr David Pollard, Head of Advanced Materials and Processing, which is one of the three pillars of the newly formed Sartorius Corporate Research. The other two pillars of corporate research